Reduction of serum immunoglobulin free light chains upon rituximab (anti-cd20) treatment correlates with decreased disease activity in patients with primary sjogren's syndrome

D. M. Bruining, R. P. E. Pollard, R. Moerman, P. M. Meiners, J.M. Meijer, H. J. Burgerhof, A. Vissink, F. G. M. Kroese, H. Bootsma, Johannes Burgerhof

OnderzoeksoutputAcademic

Originele taal-2English
Pagina's (van-tot)535-536
Aantal pagina's2
TijdschriftAnnals of the Rheumatic Diseases
Volume71
StatusPublished - jun-2012

Citeer dit